The HI-Light Vitiligo Trial is a clinical trial involving 517 participants aged 5 years and over with vitiligo. The purpose of this study is to test the effectiveness of home-based light therapy using hand-held units and topical steroid for the treatment of vitiligo.
The study is being led by Dr Jonathan Batchelor and Professor Kim Thomas from the Centre of Evidence Based Dermatology at The University of Nottingham, and is being co-ordinated from the Nottingham Clinical Trials Unit.
We hope to be able to publish the results of the trial in the near future.
For other enquiries, please email hilight@nottingham.ac.uk
Vitiligo is a skin condition that causes white patches on the skin. It affects around 0.5%-1.0% of the population worldwide, both children and adults.
People with a few relatively small patches of vitiligo, and at least one patch that has appeared or has enlarged in the last 12 months, were invited to participate in the trial. In total, 517 adults and children (5+ years of age) took part across the UK.
Steroid ointment (applied to the skin) and home-based light therapy were tested in this study. These two treatments were used either by themselves or in combination, in order to see if combination treatment works better than either treatment alone.
In order to prevent anyone from guessing a participant’s treatment, dummy UVB devices and placebo steroid ointment were used.
Pilot HI-Light TrialHi-Light Protocol Development of the Vitiligo Noticeability Scale Validation of the Vitiligo Noticeability Scale
Disclaimer: This is an independent trial that is being funded by the National Institute for Health Research Health Technology Assessment Programme (Application Reference 12/24/02). The views expressed on this website are those of the author(s) and not necessarily those of the NIHR. The study has been developed with the help and support of the UK Dermatology Clinical Trials Network (UK DCTN). Based at the University of Nottingham, the UK DCTN is a collaborative group of over 700 dermatologists, nurses, primary care staff, health care researchers and patients/carers. The aim of the Network is simple – to develop independent, high quality randomised controlled clinical trials of interventions for the treatment or prevention of skin disease. For further information please see the UK DCTN website - www.ukdctn.org.
The University of Nottingham King's Meadow Campus Lenton Lane Nottingham, NG7 2NR
telephone: +44 (0) 115 823 1048 email:cebd@nottingham.ac.uk
Browser does not support script.